Mood stabilizers in children and adolescents with autism spectrum disorders

Clinical Neuropharmacology

Volumn 38, Issue 5, 2015, Pages 177-182

  Canitano, Roberto ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Autism spectrum disorders; Behavioral disorders; Children and adolescents; Mood disorders; Mood stabilizers

Indexed keywords

ACETYLCYSTEINE; ARBACLOFEN; BUMETANIDE; ETIRACETAM; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OXCARBAZEPINE; TOPIRAMATE; VALPROIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; BACLOFEN; DIURETIC AGENT; SCAVENGER;

ADOLESCENT; AUTISM; BEHAVIOR; BEHAVIOR DISORDER; CHILD; CLINICAL TRIAL (TOPIC); DRUG TOLERABILITY; EEG ABNORMALITY; ELECTROENCEPHALOGRAM; FEASIBILITY STUDY; HUMAN; MOOD DISORDER; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; AUTISM SPECTRUM DISORDER; COMPLICATION; MOOD DISORDERS;

ACETYLCYSTEINE; ADOLESCENT; ANTICONVULSANTS; AUTISM SPECTRUM DISORDER; BACLOFEN; BUMETANIDE; CHILD; DIURETICS; FREE RADICAL SCAVENGERS; GABA-B RECEPTOR AGONISTS; HUMANS; LITHIUM; MOOD DISORDERS;

EID: 84941919695     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000096     Document Type: Review

References (48)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC; 2000.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
3. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 2006;36(8):1101-1114.
4. Matson JL, Williams LW. Depression and mood disorders among persons with autism spectrum disorders. Res Dev Disabil 2014;35(9):2003-2007.
5. Simonoff E, Jones CR, Pickles A, et al. Severe mood problems in adolescents with autism spectrum disorder. J Child Psychol Psychiatry 2012;53(11):1157-1166.
6. Rosenberg RE, Kaufmann WE, Law JK, et al. Parent report of community psychiatric comorbid diagnoses in autism spectrum disorders. Autism Res Treat 2011;2011:405849.
7. Joshi G, Biederman J, Petty C, et al. Examining the comorbidity of bipolar disorder and autism spectrum disorders: a large controlled analysis of phenotypic and familial correlates in a referred population of youth with bipolar I disorder with and without autism spectrum disorders. J Clin Psychiatry 2013;74(6):578-586.
8. Magnuson KM, Constantino JN. Characterization of depression in children with autism spectrum disorders. J Dev Behav Pediatr 2011;32(4):332-340.
9. Mazzone L, Ruta L, Reale L. Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges. Ann Gen Psychiatry 2012;11(1):16.
10. Davis NO, Kollins SH. Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics 2012;9(3):518-530.
11. Fosi T, Lax-Pericall MT, Scott RC, et al. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. Epilepsia 2013;54:2071-2081.
12. Santos K, Palmini A, Radziuk AL, et al. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol 2013;55(7):654-660.
13. Baribeau DA, Anagnostou E. An update on medication management of behavioral disorders in autism. Curr Psychiatry Rep 2014;16(3):437.
14. Hill AP, Zuckerman KE, Hagen AD, et al. Aggressive Behavior Problems in Children with Autism Spectrum Disorders: Prevalence and Correlates in a Large Clinical Sample. Res Autism Spectr Disord 2014;8(9):1121-1133.
15. Stigler KA. Psychopharmacologic management of serious behavioral disturbance in ASD. Child Adolesc Psychiatr Clin N Am 2014;23(1):73-82.
16. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302(16):1765-1773.
17. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011;21(6):517-535.
18. Jolin EM, Weller RA, Weller EB. Occurrence of affective disorders compared to other psychiatric disorders in children and adolescents with 22q11.2 deletion syndrome. J Affect Disord 2012;136(3):222-228.
19. Tuchman R. Autism and social cognition in epilepsy: implications for comprehensive epilepsy care. Curr Opin Neurol 2013;26:214-218.
20. Frye RE, Rossignol D, Casanova MF, et al. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front Public Health 2013;1:31.
21. Spence SJ, Schneider MT. The role of epilepsy and epileptiform EEGs in autism spectrum disorders. Pediatr Res 2009;65:599-606.
22. Mulligan C, Trauner D. Incidence and behavioral correlates of epileptiform abnormalities in autism spectrum disorders. J Autism Dev Disord 2014;44:452-458.
23. Hartley-McAndrew M, Weinstock A. Autism Spectrum Disorder: Correlation between aberrant behaviors, EEG abnormalities and seizures. Neurol Int 2010;2(1):e10.
24. Hirota T, Veenstra-Vanderweele J, Hollander E, et al. Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis. J Autism Dev Disord 2014;44(4):948-957.
25. Hollander E, Dolgoff-Kaspar R, Cartwright C, et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001;62(7):530-534.
26. Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006;9(2):209-213.
27. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010;35(4):990-998.
28. Anagnostou E, Esposito K, Soorya L, et al. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. J Clin Psychopharmacol 2006;26(4):444-446.
29. Hellings JA, Weckbaugh M, Nickel EJ, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15(4):682-692.
30. Hellings JA. Much improved outcome with gabapentin-divalproex combination in adultswith bipolar disorders and developmental disabilities. J Clin Psychopharmacol 2006;26(3):344-346.
31. Douglas JF, Sanders KB, Benneyworth MH, et al. Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder. J Autism Dev Disord 2013;43(5):1243-1247.
32. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr 2002;23(4):225-230.
33. Wasserman S, Iyengar R, Chapllin WF, et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006;21(6):363-367.
34. Camacho A, Espín JC, Nuñez N, et al. Levetiracetam-induced reversible autistic regression. Pediatr Neurol 2012;47(1):65-67.
35. Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001;31(2):175-181.
36. Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005;27(3):228-232.
37. Mazzone L, Ruta L. Topiramate in children with autistic spectrum disorders. Brain Dev 2006;28(10):668.
38. Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(7):1269-1272.
39. Siegel M, Beresford CA, Bunker M, et al. Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. J Child Adolesc Psychopharmacol 2014;24(7):399-402.
40. Erickson CA, Veenstra-Vanderweele JM, Melmed RD, et al. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord 2014;44(4):958-964.
41. Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012;2:e202.
42. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012;71(11):956-961.
43. Stahl SM. Mood stabilizers: Lithium. In: Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. New York, NY: Cambridge University Press; 2013:371-373.
44. Kerbeshian J, Burd L, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol 1987;7(6):401-405.
45. Steingard R, Biederman J. Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. J Am Acad Child and Adolesc Psychiatry 1987;26(6):932-935.
46. Coghlan S, Horder J, Inkster B, et al. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev 2012;36(9):2044-2055.
47. Chadman KK, Guariglia SR, Yoo JH. New directions in the treatment of autism spectrum disorders from animal model research. Expert Opin Drug Discov 2012;7(5):407-416.
48. Frye RE. Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. Drug Health care Patient Saf 2014;10:69-76.